Back to News
Market Impact: 0.2
Pilatus Biosciences Strengthens Global Intellectual Property Position for Lead CD36-Targeted Immunometabolic Therapy
Source: Business Wire
Healthcare & BiotechPatents & Intellectual Property
Pilatus Biosciences announced that it has strengthened the global intellectual-property position for PLT012, its lead CD36-targeted immunotherapy. The announcement supports protection of the company’s lead oncology-development asset, although no clinical data, financial terms, or commercialization timeline were disclosed.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
More News
- Stock Movers: Chime, Stryker, Compass Pathways (Podcast)
- Attacks Halt Saudi Energy Sites, Novartis Drops Most in 6 Years | The Opening Trade 9/8/2026
- Pharma major plummets over 10% after third trial disappointment in a week
- Kaplan Fox Continues to Alert Investors of Hims & Hers Health, Inc. (NYSE: HIMS) to a Class Action Deadline on November 2, 2026
- Stock Movers: SpaceX, Qualcomm, Roivant (Podcast)
- Novartis Stock Drops as Trial Failures Ripple Across Biotech Partners